Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Enterprise Value (2016 - 2025)

Haemonetics has reported Enterprise Value over the past 17 years, most recently at -$363.4 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 13.25% year-over-year to -$363.4 million; the TTM value through Dec 2025 reached -$363.4 million, down 13.25%, while the annual FY2025 figure was -$306.8 million, 71.57% down from the prior year.
  • Enterprise Value for Q4 2025 was -$363.4 million at Haemonetics, down from -$296.4 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$173.5 million in Q3 2021 and troughed at -$363.4 million in Q4 2025.
  • A 5-year average of -$262.6 million and a median of -$272.0 million in 2022 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: surged 37.15% in 2024 and later plummeted 71.57% in 2025.
  • Year by year, Enterprise Value stood at -$192.4 million in 2021, then fell by 16.41% to -$224.0 million in 2022, then increased by 13.4% to -$194.0 million in 2023, then tumbled by 65.4% to -$320.8 million in 2024, then decreased by 13.25% to -$363.4 million in 2025.
  • Business Quant data shows Enterprise Value for HAE at -$363.4 million in Q4 2025, -$296.4 million in Q3 2025, and -$292.9 million in Q2 2025.